DNAJC5 and malaria: When combined with the appropriate antigen, CAF09b (low dose MMG/poly(I:C)) has also shown promise in vaccines for malaria (recombinant malaria antigen CSP) [216] as an adjuvant for intranasal whole inactivated virus (WIV) influenza H1N1 vaccine [166], and has entered clinical trials for vaccination against chlamydia using the CTH522 subunit vaccine (Table 4) where it has demonstrated safety and immunogenicity when administered i.m. followed by homologous i.m. boosts, or with boosting via intradermal or topical ocular administration of CTH522 alone [138,217].